Catalent (CTLT) Cut to “Equal Weight” at Stephens
Catalent (NYSE:CTLT) was downgraded by analysts at Stephens from an “overweight” rating to an “equal weight” rating in a note issued to investors on Tuesday, MarketBeat.com reports.
CTLT has been the subject of several other research reports. Royal Bank of Canada set a $48.00 target price on shares of Catalent and gave the stock a “buy” rating in a report on Monday. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. Goldman Sachs Group assumed coverage on shares of Catalent in a report on Wednesday, January 24th. They issued a “buy” rating and a $50.00 target price for the company. Piper Jaffray Companies raised their target price on shares of Catalent from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Tuesday, November 7th. Finally, ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $45.60.
Catalent (NYSE:CTLT) opened at $41.23 on Tuesday. Catalent has a 12-month low of $27.48 and a 12-month high of $47.87. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91. The company has a market cap of $5,799.36, a price-to-earnings ratio of 72.33, a price-to-earnings-growth ratio of 2.74 and a beta of 1.47.
In related news, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Uwe Roehrhoff purchased 7,500 shares of Catalent stock in a transaction that occurred on Tuesday, November 21st. The stock was bought at an average cost of $39.22 per share, for a total transaction of $294,150.00. The disclosure for this purchase can be found here. Company insiders own 1.70% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of CTLT. Zions Bancorporation purchased a new position in Catalent during the 3rd quarter valued at about $100,000. First Bank & Trust increased its position in Catalent by 54.2% during the 4th quarter. First Bank & Trust now owns 3,764 shares of the company’s stock valued at $155,000 after purchasing an additional 1,323 shares during the period. Fortaleza Asset Management Inc. purchased a new position in Catalent during the 3rd quarter valued at about $164,000. Advisor Group Inc. increased its position in Catalent by 1.3% during the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock valued at $180,000 after purchasing an additional 65 shares during the period. Finally, CAPROCK Group Inc. purchased a new position in Catalent during the 4th quarter valued at about $203,000. 98.86% of the stock is currently owned by institutional investors and hedge funds.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.